共 50 条
- [21] Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Zhao, JunFang, JianYu, YanChu, QianLi, XiaoyanChen, JiayanLiu, ZheZhang, LiWu, LinZhuang, WuLi, XingYaZhao, YanqiuXing, LigangLiu, LianBai, ChunmeiDong, XiaorongSong, QibinPan, PinghuaFang, XuefengWang, Jie
- [22] Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced nonsmall cell lung cancer and other solid tumorsCANCER RESEARCH, 2023, 83 (07)Zhu, BingCui, DaweiLiu, RuifengFeng, WeidongSheng, ZelinLv, Binhua
- [23] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Govindan, RamaswamyAwad, Mark M.Gadgeel, Shirish M.Pachter, Jonathan A.Patrick, GloriaDenis, Louis J.
- [24] A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+solid tumorsMOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)Schlechter, BenjaminDumbrava, EcaterinaSaibil, SamuelGutierez, MartinIqbal, SymaSohal, DavendraApostolopoulou, MariaMoss, KaraAdib, DeyaaOlson, Daniel
- [25] A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+solid tumorsCANCER RESEARCH, 2024, 84 (07)Dumbrava, Ecaterina E.Olson, DanielSaibil, SamuelSohal, Davendra P.Iqbal, SymaUrgelles, AlejandroApostolopoulou, MariaMueller, AmyMoss, KaraAdib, DeyaaSchlecter, Ben
- [26] AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trialANNALS OF ONCOLOGY, 2020, 31 : S226 - S226Strickler, J.Fakih, M.Price, T.Desai, J.Durm, G.Krauss, J.Kuboki, Y.Kim, T.Sacher, A.Henary, H.Kim, J.Hong, D.
- [27] A PHASE 1/2 STUDY OF ASP1570 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON, OR ARE INELIGIBLE FOR, ALL AVAILABLE STANDARD THERAPIESJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A786 - A786Patel, ManishPark, DavidTarantolo, StefanoDowlati, AfshinOlson, DanielKaneko, YuichiroTang, MeiSoukharev, SergueiTakizawa, MasaomiOkada, YoheiFredericks, ChristineSmith, DerekFlegel, TeresaWatanabe, TsubasaLee, SueLuke, Jason
- [28] KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Sabari, Joshua K.Park, HaeseongTolcher, Anthony W.Ou, Sai-Hong IgnatiusGaron, Edward B.George, BenJanne, Pasi A.Moody, Susan ElizabethTan, Eugene Y.Sen, Suman KumarPeters, DanaYan, XiaohongChristensen, James G.Chi, Andrew S.Heist, Rebecca Suk
- [29] A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutationANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1273Zhou, C.Li, W.Song, Z.Zhang, Y.Zhang, Y.Huang, D.Yang, Z.Zhou, M.Mao, R.Huang, C.Li, X.Wang, J.
- [30] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid TumorsMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Ramalingam, SureshFakih, MarwanStrickler, JohnGovindan, RamaswamyLi, Bob T.Goldberg, SarahGandara, DavidBurns, TimothyBarve, MinalShu, CatherineFrank, RichardSohal, DavendraJafarinasabian, PegahDai, TianMather, OmarHong, David